glp-1 drugs key developments 2025 Clinical Practice Updates: December GLP-1 Pipeline Update: November 2025
Description
To address this, a correlation coefficient ( r ) of 0.5 was used to estimate the mean and SD change in BMI reduction outcome
Aminoalkyl-Containing Analogs Katarzyna Kaczanowska et al
Sitagliptin reduces albuminuria in patients with type 2 diabetes
The oral segment is projected to witness the fastest CAGR from 2025 to 2032, driven by the growing demand for needle-free alternatives and the launch of oral GLP-1 receptor agonists such as Rybelsus (oral semaglutide) and future pipeline products such as orforglipron
10.1007/s13300-024-01674-8 58 OngK
